Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Cancer Clear all

Conditions: Urinary Bladder Neoplasm
Interventions: Mitomycin C; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Mycoses
Interventions: Voriconazole; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Interventions: UGN-103; Drug
Lead sponsor: UroGen Pharma Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 17
States / cities: Loma Linda, California • San Diego, California • Washington D.C., District of Columbia + 12 more

Conditions: Invasive Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions: Biopsy of Breast; Procedure
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 377
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 256 more

Conditions: Bladder Cancer
Interventions: Ethacrynic Acid; Drug
Lead sponsor: Eugene Lee, MD; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Atezolizumab, Biopsy of Bladder, Cisplatin, Computed Tomography, Cystoscopy, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Quality-of-Life Assessment, Radiation Therapy, Survey Administration, Transurethral Resection of Bladder Tumor; Drug · Procedure · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 365
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 273 more

Conditions: Cancer
Interventions: Minimally-Invasive Procedure; Procedure
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Bladder Cancer, Metastatic Bladder Cancer, Invasive Bladder Cancer
Interventions: Avelumab; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Bladder Cancer
Interventions: Nivolumab, Ipilimumab, Radical cystectomy; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions: Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration; Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 50 Years and older · Female only
Enrollment: 928 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 15
States / cities: Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 11 more

Conditions: Lymphoma
Interventions: Cardiac Magnetic Resonance Scan; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer
Interventions: Viewray MRIdian® Linac; Radiation
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Bladder Cancer, Recurrent Bladder Cancer, Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Tampa, Florida • Iowa City, Iowa • Chapel Hill, North Carolina + 3 more

Conditions: Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
Interventions: Palbociclib, Bazedoxifene; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions: ABI-009, Gemcitabine; Drug
Lead sponsor: Aadi Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Recurrent Cervical Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Corpus Sarcoma, Stage I Uterine Corpus Cancer, Stage I Uterine Sarcoma, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Uterine Corpus Cancer, Stage II Uterine Sarcoma, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Uterine Sarcoma, Stage IV Uterine Corpus Cancer, Stage IV Uterine Sarcoma, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions: Medical Chart Review, Questionnaire Administration; Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: Female only
Enrollment: 778 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 167
States / cities: Phoenix, Arizona • Tucson, Arizona • Burbank, California + 122 more

Conditions: High Risk for Invasive Breast Cancer
Interventions: Tamoxifen, Tamoxifen (Nolvadex); Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 30 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Uterine Leiomyoma, Fibroids
Interventions: Pirfenidone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 35 Years to 50 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bladder Cancer
Interventions: Enzalutamide; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Invasive Breast Carcinoma, Non-Metastatic Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions: Quality-of-Life Assessment, Questionnaire Administration, Radiation Boost, Therapeutic Surgical Procedure, Whole Breast Irradiation, Breast MRI; Other · Radiation · Procedure
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 11
States / cities: Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 7 more

Conditions: Early-stage Breast Cancer, Invasive Ductal Carcinoma of Female Breast
Interventions: Partial Breast Irradiation (PBI); Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 40 Years and older · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: New York, New York

Conditions: Esophageal Cancer
Interventions: ArabinoFuranosylGuanine [18F]F-AraG; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bladder Cancer, Muscle-invasive Bladder Cancer
Interventions: Methotrexate, Doxorubicin, vinblastine, cisplatin, Pegfilgrastim; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 4
States / cities: Boston, Massachusetts • Burlington, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Breast Cancer
Interventions: Accelerated partial breast irradiation, Extended Follow up; Radiation · Other
Lead sponsor: Jaroslaw Hepel; Other
Eligibility: 50 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 4
States / cities: Lakeland, Florida • Providence, Rhode Island • Tacoma, Washington

Search by objective public record fields.

Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer

Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery

Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer

A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Cardiac Fibrosis by CMR in Patients With Cancer

CONFIRM: Magnetic Resonance Guided Radiation Therapy

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer

SHORTened Duration of TAMoxifen

Development of a Non-Invasive Treatment for Uterine Leiomyoma (Fibroids)

Enzalutamide for Bladder Cancer Chemoprevention

Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer

Radiation After No Axillary Nodal Sampling

18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer